Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab accelerated induction in pediatric ulcerative colitis (INDUCE)
NCT03209232Terminated
- Sponsor
- Schneider Children's Medical Center of Israel
- Start
- Apr 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab in ulcerative colitis (UC) (2 arms), sponsored by Schneider Children's Medical Center of Israel. Primary endpoint: Clinical remission on infliximab at 20 weeks. Started Apr 2018; status: terminated.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03209232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03209232.